|
G |
Adh1c |
alcohol dehydrogenase 1C (class I), gamma polypeptide |
multiple interactions |
ISO |
Cyanamide promotes the reaction [[ADH1 protein co-treated with Ethanol] results in increased abundance of Acetaldehyde]; Cyanamide promotes the reaction [[ADH1 protein results in increased metabolism of Ethanol] which results in increased chemical synthesis of Acetaldehyde] |
CTD |
PMID:7646056 PMID:11981770 |
|
NCBI chr 2:226,797,303...226,808,892
Ensembl chr 2:226,797,303...226,808,892
|
|
G |
Aldh2 |
aldehyde dehydrogenase 2 family member |
multiple interactions decreases activity |
ISO EXP |
[Cyanamide results in decreased activity of ALDH2 protein] which results in decreased metabolism of Nitroglycerin Cyanamide affects the reaction [[lead acetate results in increased abundance of Lead] affects the reaction [Ethanol affects the expression of ALDH2 protein]]; Cyanamide affects the reaction [[lead acetate results in increased abundance of Lead] which affects the expression of ALDH2 protein]; Cyanamide affects the reaction [Ethanol affects the expression of ALDH2 protein] |
CTD |
PMID:14690875 PMID:18272654 PMID:19576883 PMID:31550440 |
|
NCBI chr12:34,949,549...34,982,527
Ensembl chr12:34,901,219...34,982,521
|
|
G |
Avp |
arginine vasopressin |
multiple interactions increases expression |
EXP |
[Ethanol co-treated with Cyanamide] results in increased expression of AVP mRNA Cyanamide increases expression of Avp mRNA in the paraventricular nucleus of hypothalamus Cyanamide results in increased expression of AVP mRNA |
CTD RGD |
PMID:10718921 PMID:10978654 PMID:11139417 PMID:10718921 |
RGD:408426010 |
NCBI chr 3:117,793,447...117,805,091
Ensembl chr 3:117,793,457...117,795,425
|
|
G |
Bax |
BCL2 associated X, apoptosis regulator |
increases expression |
EXP |
Cyanamide results in increased expression of BAX mRNA |
CTD |
PMID:12003908 |
|
NCBI chr 1:95,940,001...95,945,407
Ensembl chr 1:95,938,808...95,945,368
|
|
G |
Bcl2 |
BCL2, apoptosis regulator |
multiple interactions |
EXP |
[Ethanol co-treated with Cyanamide] results in increased expression of BCL2 mRNA |
CTD |
PMID:12003908 |
|
NCBI chr13:22,689,783...22,853,920
Ensembl chr13:22,684,989...22,853,743 Ensembl chr13:22,684,989...22,853,743
|
|
G |
Bmp7 |
bone morphogenetic protein 7 |
multiple interactions |
ISO |
Cyanamide inhibits the reaction [CGA protein results in increased expression of BMP7 mRNA] |
CTD |
PMID:22285649 |
|
NCBI chr 3:161,639,915...161,716,938
Ensembl chr 3:161,516,462...161,716,788
|
|
G |
Ccnd2 |
cyclin D2 |
multiple interactions |
ISO |
Cyanamide inhibits the reaction [CGA protein results in increased expression of CCND2 mRNA] |
CTD |
PMID:22285649 |
|
NCBI chr 4:159,966,883...159,989,261
Ensembl chr 4:159,962,363...159,989,495
|
|
G |
Cdkn1a |
cyclin-dependent kinase inhibitor 1A |
multiple interactions |
EXP |
[Ethanol co-treated with Cyanamide] results in decreased expression of CDKN1A mRNA |
CTD |
PMID:12003908 |
|
NCBI chr20:7,149,177...7,159,727
Ensembl chr20:7,149,217...7,159,585
|
|
G |
Cga |
glycoprotein hormones, alpha polypeptide |
multiple interactions |
ISO |
Cyanamide inhibits the reaction [CGA protein results in increased expression of BMP7 mRNA]; Cyanamide inhibits the reaction [CGA protein results in increased expression of CCND2 mRNA]; Cyanamide inhibits the reaction [CGA protein results in increased expression of CYP17A1 mRNA]; Cyanamide inhibits the reaction [CGA protein results in increased expression of CYP19A1 mRNA]; Cyanamide inhibits the reaction [CGA protein results in increased expression of FSHR mRNA]; Cyanamide inhibits the reaction [CGA protein results in increased expression of LHCGR mRNA] |
CTD |
PMID:22285649 |
|
NCBI chr 5:49,486,915...49,499,192
Ensembl chr 5:49,487,068...49,499,191
|
|
G |
Chat |
choline O-acetyltransferase |
multiple interactions |
EXP |
Cyanamide affects the reaction [Ethanol results in decreased expression of CHAT mRNA]; Cyanamide affects the reaction [Ethanol results in decreased expression of CHAT protein] |
CTD |
PMID:17045751 |
|
NCBI chr16:7,657,362...7,717,093
Ensembl chr16:7,657,362...7,717,093
|
|
G |
Crh |
corticotropin releasing hormone |
multiple interactions increases expression |
EXP |
[Cyanamide co-treated with Ethanol] results in increased expression of CRH mRNA; [Ethanol co-treated with Cyanamide] results in increased expression of CRH mRNA Cyanamide results in increased expression of CRH mRNA |
CTD |
PMID:10718921 PMID:10978654 PMID:11139417 PMID:12217933 PMID:16375214 |
|
NCBI chr 2:102,143,055...102,144,919
Ensembl chr 2:102,143,055...102,144,919
|
|
G |
Ctsk |
cathepsin K |
multiple interactions |
ISO |
Cyanamide analog binds to and results in decreased activity of CTSK protein |
CTD |
PMID:15896958 |
|
NCBI chr 2:183,058,586...183,069,551
Ensembl chr 2:183,058,569...183,069,550
|
|
G |
Cyp17a1 |
cytochrome P450, family 17, subfamily a, polypeptide 1 |
multiple interactions |
ISO |
Cyanamide inhibits the reaction [CGA protein results in increased expression of CYP17A1 mRNA] |
CTD |
PMID:22285649 |
|
NCBI chr 1:245,535,462...245,543,148
Ensembl chr 1:245,535,462...245,541,573
|
|
G |
Cyp19a1 |
cytochrome P450, family 19, subfamily a, polypeptide 1 |
multiple interactions |
ISO |
Cyanamide inhibits the reaction [CGA protein results in increased expression of CYP19A1 mRNA] |
CTD |
PMID:22285649 |
|
NCBI chr 8:54,552,978...54,580,375
Ensembl chr 8:54,553,165...54,580,758
|
|
G |
Eif4ebp1 |
eukaryotic translation initiation factor 4E binding protein 1 |
multiple interactions |
ISO |
Cyanamide inhibits the reaction [Ethanol results in decreased phosphorylation of EIF4EBP1 protein] |
CTD |
PMID:18317950 |
|
NCBI chr16:64,792,595...64,805,984
Ensembl chr16:64,790,226...64,805,984
|
|
G |
Fos |
Fos proto-oncogene, AP-1 transcription factor subunit |
multiple interactions increases expression |
EXP |
[Acetaldehyde co-treated with Cyanamide] results in increased expression of FOS protein; Acetaldehyde promotes the reaction [Cyanamide results in increased expression of FOS protein]; candesartan inhibits the reaction [[Acetaldehyde co-treated with Cyanamide] results in increased expression of FOS protein]; candesartan inhibits the reaction [Acetaldehyde promotes the reaction [Cyanamide results in increased expression of FOS protein]] |
CTD |
PMID:26298003 |
|
NCBI chr 6:105,121,170...105,124,036
Ensembl chr 6:105,121,170...105,124,036
|
|
G |
Fshr |
follicle stimulating hormone receptor |
multiple interactions |
ISO |
Cyanamide inhibits the reaction [CGA protein results in increased expression of FSHR mRNA] |
CTD |
PMID:22285649 |
|
NCBI chr 6:5,198,825...5,406,785
Ensembl chr 6:5,198,825...5,406,785
|
|
G |
Igfbp1 |
insulin-like growth factor binding protein 1 |
multiple interactions |
EXP |
Cyanamide inhibits the reaction [Ethanol results in increased expression of IGFBP1 mRNA] |
CTD |
PMID:12394292 |
|
NCBI chr14:82,047,415...82,052,482
Ensembl chr14:82,047,415...82,052,482
|
|
G |
Lhcgr |
luteinizing hormone/choriogonadotropin receptor |
multiple interactions |
ISO |
Cyanamide inhibits the reaction [CGA protein results in increased expression of LHCGR mRNA] |
CTD |
PMID:22285649 |
|
NCBI chr 6:5,661,871...5,728,109
Ensembl chr 6:5,661,871...5,724,521
|
|
G |
Map1lc3b |
microtubule-associated protein 1 light chain 3 beta |
multiple interactions increases lipidation |
ISO |
Cyanamide promotes the reaction [Acetaldehyde results in increased lipidation of MAP1LC3B protein] Cyanamide results in increased lipidation of MAP1LC3B protein |
CTD |
PMID:24492484 |
|
NCBI chr19:49,665,795...49,673,655
Ensembl chr19:49,665,791...49,677,690 Ensembl chr16:49,665,791...49,677,690
|
|
G |
Mitf |
melanocyte inducing transcription factor |
decreases expression |
ISO |
Cyanamide results in decreased expression of MITF mRNA |
CTD |
PMID:23489423 |
|
NCBI chr 4:130,409,020...130,621,145
Ensembl chr 4:130,409,217...130,621,145
|
|
G |
Myc |
MYC proto-oncogene, bHLH transcription factor |
multiple interactions |
EXP |
[Cyanamide co-treated with Ethanol] results in increased expression of MYC mRNA |
CTD |
PMID:12876071 |
|
NCBI chr 7:93,593,705...93,598,633
Ensembl chr 7:93,593,705...93,598,630
|
|
G |
Nat1 |
N-acetyltransferase 1 |
multiple interactions decreases activity |
ISO |
Acetyl Coenzyme A inhibits the reaction [Cyanamide results in decreased activity of NAT1 protein] |
CTD |
PMID:22835378 |
|
NCBI chr16:22,218,217...22,238,516
Ensembl chr16:22,208,194...22,238,520
|
|
G |
Nppa |
natriuretic peptide A |
multiple interactions |
EXP |
[Ethanol co-treated with Cyanamide] results in increased expression of NPPA mRNA |
CTD |
PMID:10905996 |
|
NCBI chr 5:158,429,042...158,430,351
Ensembl chr 5:158,429,042...158,430,351
|
|
G |
Pomc |
proopiomelanocortin |
multiple interactions increases expression |
EXP |
[Cyanamide co-treated with Ethanol] results in increased expression of POMC mRNA; [Ethanol co-treated with Cyanamide] results in decreased expression of POMC mRNA; [Ethanol co-treated with Cyanamide] results in increased expression of POMC mRNA Cyanamide results in increased expression of POMC mRNA |
CTD |
PMID:10978654 PMID:11139417 PMID:16375214 |
|
NCBI chr 6:26,939,844...26,945,666
Ensembl chr 6:26,939,837...26,945,664
|
|
G |
Ppara |
peroxisome proliferator activated receptor alpha |
multiple interactions |
EXP |
Cyanamide promotes the reaction [Ethanol results in decreased activity of PPARA protein] |
CTD |
PMID:11022051 |
|
NCBI chr 7:116,832,405...116,900,878
Ensembl chr 7:116,832,756...116,895,346
|
|
G |
Pparg |
peroxisome proliferator-activated receptor gamma |
multiple interactions |
ISO |
Cyanamide inhibits the reaction [Ethanol inhibits the reaction [rosiglitazone results in increased activity of PPARG protein]] |
CTD |
PMID:17030193 |
|
NCBI chr 4:148,423,102...148,548,471
Ensembl chr 4:148,423,194...148,548,468
|
|
G |
Ren |
renin |
multiple interactions |
EXP |
[Acetaldehyde co-treated with Cyanamide] results in increased activity of REN protein |
CTD |
PMID:26298003 |
|
NCBI chr13:44,796,260...44,807,491
Ensembl chr13:44,796,091...44,807,489
|
|
G |
Tp53 |
tumor protein p53 |
multiple interactions |
EXP |
[Ethanol co-treated with Cyanamide] results in increased expression of TP53 mRNA |
CTD |
PMID:12003908 |
|
NCBI chr10:54,300,070...54,311,525
Ensembl chr10:54,300,048...54,311,524
|
|
G |
Tyr |
tyrosinase |
decreases expression |
ISO |
Cyanamide results in decreased expression of TYR mRNA |
CTD |
PMID:23489423 |
|
NCBI chr 1:141,115,036...141,210,207
Ensembl chr 1:141,115,036...141,210,207
|
|
|
G |
A2m |
alpha-2-macroglobulin |
increases expression |
EXP |
melamine results in increased expression of A2M |
CTD |
PMID:23052191 |
|
NCBI chr 4:154,897,770...154,947,787
Ensembl chr 4:154,897,877...154,947,786
|
|
G |
Alb |
albumin |
multiple interactions |
EXP |
[melamine co-treated with cyanuric acid] results in increased expression of ALB protein |
CTD |
PMID:22610612 |
|
NCBI chr14:17,607,397...17,622,814
Ensembl chr14:17,607,381...17,622,836
|
|
G |
Bad |
BCL2-associated agonist of cell death |
multiple interactions increases expression |
ISO |
1,2-Dihydroxybenzene-3,5-Disulfonic Acid Disodium Salt inhibits the reaction [melamine results in increased expression of BAD protein]; manganese(III)-tetrakis(4-benzoic acid)porphyrin inhibits the reaction [melamine results in increased expression of BAD protein]; TGFB1 protein affects the reaction [melamine results in increased expression of BAD protein] |
CTD |
PMID:22915474 |
|
NCBI chr 1:204,133,502...204,142,829
Ensembl chr 1:204,131,501...204,142,823
|
|
G |
Bax |
BCL2 associated X, apoptosis regulator |
multiple interactions decreases expression increases expression |
ISO |
1,2-Dihydroxybenzene-3,5-Disulfonic Acid Disodium Salt inhibits the reaction [melamine results in increased expression of BAX protein]; manganese(III)-tetrakis(4-benzoic acid)porphyrin inhibits the reaction [melamine results in increased expression of BAX protein]; TGFB1 protein affects the reaction [melamine results in increased expression of BAX protein] melamine results in decreased expression of BAX protein |
CTD |
PMID:22915474 PMID:29254411 |
|
NCBI chr 1:95,940,001...95,945,407
Ensembl chr 1:95,938,808...95,945,368
|
|
G |
Bcl2 |
BCL2, apoptosis regulator |
decreases expression increases expression |
ISO |
melamine results in decreased expression of BCL2 protein melamine results in increased expression of BCL2 protein |
CTD |
PMID:22915474 PMID:29254411 |
|
NCBI chr13:22,689,783...22,853,920
Ensembl chr13:22,684,989...22,853,743 Ensembl chr13:22,684,989...22,853,743
|
|
G |
Bcl2l1 |
Bcl2-like 1 |
decreases expression |
ISO |
melamine results in decreased expression of BCL2L1 protein |
CTD |
PMID:22915474 |
|
NCBI chr 3:141,253,508...141,304,582
Ensembl chr 3:141,253,523...141,303,479 Ensembl chr 1:141,253,523...141,303,479
|
|
G |
Casp3 |
caspase 3 |
multiple interactions decreases expression increases cleavage |
ISO |
1,2-Dihydroxybenzene-3,5-Disulfonic Acid Disodium Salt inhibits the reaction [melamine results in increased cleavage of CASP3 protein]; manganese(III)-tetrakis(4-benzoic acid)porphyrin inhibits the reaction [melamine results in increased cleavage of CASP3 protein]; TGFB1 protein affects the reaction [melamine results in increased cleavage of CASP3 protein] melamine results in decreased expression of CASP3 protein |
CTD |
PMID:22915474 PMID:29254411 |
|
NCBI chr16:45,662,910...45,681,171
Ensembl chr16:45,662,910...45,684,648
|
|
G |
Casp9 |
caspase 9 |
multiple interactions increases cleavage |
ISO |
1,2-Dihydroxybenzene-3,5-Disulfonic Acid Disodium Salt inhibits the reaction [melamine results in increased cleavage of CASP9 protein]; manganese(III)-tetrakis(4-benzoic acid)porphyrin inhibits the reaction [melamine results in increased cleavage of CASP9 protein]; TGFB1 protein affects the reaction [melamine results in increased cleavage of CASP9 protein] |
CTD |
PMID:22915474 |
|
NCBI chr 5:154,108,872...154,126,628
Ensembl chr 5:154,109,046...154,126,626
|
|
G |
Ccl2 |
C-C motif chemokine ligand 2 |
multiple interactions increases expression |
ISO |
1,2-Dihydroxybenzene-3,5-Disulfonic Acid Disodium Salt inhibits the reaction [melamine results in increased expression of CCL2 mRNA]; 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [melamine results in increased expression of CCL2 mRNA]; manganese(III)-tetrakis(4-benzoic acid)porphyrin inhibits the reaction [melamine results in increased expression of CCL2 mRNA]; SB 203580 inhibits the reaction [melamine results in increased expression of CCL2 mRNA]; SN50 peptide inhibits the reaction [melamine results in increased expression of CCL2 mRNA] |
CTD |
PMID:22915474 |
|
NCBI chr10:67,005,424...67,007,222
Ensembl chr10:67,005,424...67,007,226
|
|
G |
Cd44 |
CD44 molecule |
increases expression |
EXP |
melamine results in increased expression of CD44; melamine results in increased expression of CD44 protein |
CTD |
PMID:23052191 PMID:33211169 |
|
NCBI chr 3:89,155,850...89,244,615
Ensembl chr 3:89,157,058...89,244,620
|
|
G |
Clu |
clusterin |
multiple interactions increases expression |
EXP |
[cyanuric acid co-treated with melamine] results in increased expression of CLU mRNA; [melamine co-treated with cyanuric acid] results in increased expression of CLU mRNA; [melamine co-treated with cyanuric acid] results in increased expression of CLU protein melamine results in increased expression of CLU |
CTD |
PMID:21784140 PMID:22610612 PMID:23022069 PMID:23052191 |
|
NCBI chr15:40,161,068...40,200,315
Ensembl chr15:40,174,617...40,200,315
|
|
G |
Cyp19a1 |
cytochrome P450, family 19, subfamily a, polypeptide 1 |
increases activity |
ISO |
melamine results in increased activity of CYP19A1 protein |
CTD |
PMID:32113805 |
|
NCBI chr 8:54,552,978...54,580,375
Ensembl chr 8:54,553,165...54,580,758
|
|
G |
Fn1 |
fibronectin 1 |
multiple interactions increases expression |
ISO |
1,2-Dihydroxybenzene-3,5-Disulfonic Acid Disodium Salt inhibits the reaction [melamine results in increased expression of FN1 mRNA]; 1,2-Dihydroxybenzene-3,5-Disulfonic Acid Disodium Salt inhibits the reaction [melamine results in increased expression of FN1 protein]; manganese(III)-tetrakis(4-benzoic acid)porphyrin inhibits the reaction [melamine results in increased expression of FN1 mRNA]; manganese(III)-tetrakis(4-benzoic acid)porphyrin inhibits the reaction [melamine results in increased expression of FN1 protein]; TGFB1 protein affects the reaction [melamine results in increased expression of FN1 mRNA]; TGFB1 protein affects the reaction [melamine results in increased expression of FN1 protein] melamine results in increased expression of FN1 mRNA; melamine results in increased expression of FN1 protein |
CTD |
PMID:22915474 |
|
NCBI chr 9:73,196,044...73,264,695
Ensembl chr 9:73,196,044...73,264,678
|
|
G |
Gpnmb |
glycoprotein nmb |
increases expression |
EXP |
melamine results in increased expression of GPNMB |
CTD |
PMID:23052191 |
|
NCBI chr 4:78,010,247...78,031,491
Ensembl chr 4:78,010,197...78,049,367
|
|
G |
Grin1 |
glutamate ionotropic receptor NMDA type subunit 1 |
decreases expression |
EXP |
melamine results in decreased expression of GRIN1 protein |
CTD |
PMID:28206646 |
|
NCBI chr 3:8,103,680...8,130,603
Ensembl chr 3:8,103,680...8,130,603
|
|
G |
Grin2b |
glutamate ionotropic receptor NMDA type subunit 2B |
decreases expression |
EXP |
melamine results in decreased expression of GRIN2B protein |
CTD |
PMID:28206646 |
|
NCBI chr 4:168,580,824...169,044,110
Ensembl chr 4:168,599,546...169,042,279
|
|
G |
Havcr1 |
hepatitis A virus cellular receptor 1 |
increases expression multiple interactions |
EXP |
melamine results in increased expression of HAVCR1 [cyanuric acid co-treated with melamine] results in increased expression of HAVCR1 mRNA; [melamine co-treated with cyanuric acid] results in increased expression of HAVCR1 mRNA; [melamine co-treated with cyanuric acid] results in increased expression of HAVCR1 protein |
CTD |
PMID:21784140 PMID:22610612 PMID:23022069 PMID:23052191 |
|
NCBI chr10:31,118,667...31,151,730
Ensembl chr10:31,119,088...31,151,698
|
|
G |
Il6 |
interleukin 6 |
multiple interactions increases expression |
ISO |
1,2-Dihydroxybenzene-3,5-Disulfonic Acid Disodium Salt inhibits the reaction [melamine results in increased expression of IL6 mRNA]; 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [melamine results in increased expression of IL6 mRNA]; manganese(III)-tetrakis(4-benzoic acid)porphyrin inhibits the reaction [melamine results in increased expression of IL6 mRNA]; SB 203580 inhibits the reaction [melamine results in increased expression of IL6 mRNA]; SN50 peptide inhibits the reaction [melamine results in increased expression of IL6 mRNA] |
CTD |
PMID:22915474 |
|
NCBI chr 4:5,214,602...5,219,178
Ensembl chr 4:5,213,394...5,219,178
|
|
G |
Krt14 |
keratin 14 |
increases expression |
EXP |
melamine results in increased expression of KRT14 protein |
CTD |
PMID:33211169 |
|
NCBI chr10:85,137,786...85,142,054
Ensembl chr10:85,066,802...85,171,799
|
|
G |
Lcn2 |
lipocalin 2 |
multiple interactions increases expression |
EXP |
[cyanuric acid co-treated with melamine] results in increased expression of LCN2 mRNA; [melamine co-treated with cyanuric acid] results in increased expression of LCN2 mRNA melamine results in increased expression of LCN2 |
CTD |
PMID:21784140 PMID:23022069 PMID:23052191 |
|
NCBI chr 3:15,680,688...15,684,033
Ensembl chr 3:15,680,687...15,684,095
|
|
G |
Ldha |
lactate dehydrogenase A |
decreases activity |
ISO |
melamine results in decreased activity of LDHA protein |
CTD |
PMID:29254411 |
|
NCBI chr 1:97,371,823...97,381,247
Ensembl chr 1:97,366,021...97,433,472
|
|
G |
Mapk1 |
mitogen activated protein kinase 1 |
increases phosphorylation |
ISO |
melamine results in increased phosphorylation of MAPK1 protein |
CTD |
PMID:22915474 |
|
NCBI chr11:83,957,813...84,023,629
Ensembl chr11:83,957,813...84,023,616
|
|
G |
Mapk14 |
mitogen activated protein kinase 14 |
increases expression |
ISO |
melamine results in increased expression of MAPK14 mRNA |
CTD |
PMID:34842327 |
|
NCBI chr20:6,749,646...6,810,590
Ensembl chr20:6,749,670...6,810,589
|
|
G |
Mapk3 |
mitogen activated protein kinase 3 |
increases phosphorylation increases expression |
ISO |
melamine results in increased phosphorylation of MAPK3 protein melamine results in increased expression of MAPK3 mRNA |
CTD |
PMID:22915474 PMID:34842327 |
|
NCBI chr 1:181,366,646...181,372,863
Ensembl chr 1:181,366,637...181,372,863
|
|
G |
Mapk9 |
mitogen-activated protein kinase 9 |
increases expression |
ISO |
melamine results in increased expression of MAPK9 mRNA |
CTD |
PMID:34842327 |
|
NCBI chr10:34,169,661...34,211,138
Ensembl chr10:34,169,675...34,210,178
|
|
G |
Nfkbia |
NFKB inhibitor alpha |
increases phosphorylation |
ISO |
melamine results in increased phosphorylation of NFKBIA protein |
CTD |
PMID:22915474 |
|
NCBI chr 6:72,858,713...72,861,941
Ensembl chr 6:72,858,712...72,861,941
|
|
G |
Rela |
RELA proto-oncogene, NF-kB subunit |
increases phosphorylation |
ISO |
melamine results in increased phosphorylation of RELA protein |
CTD |
PMID:22915474 |
|
NCBI chr 1:202,925,001...202,935,484
Ensembl chr 1:202,924,945...202,935,484
|
|
G |
Sod1 |
superoxide dismutase 1 |
decreases activity |
ISO |
melamine results in decreased activity of SOD1 protein |
CTD |
PMID:29254411 |
|
NCBI chr11:29,456,673...29,462,249
Ensembl chr11:29,456,558...29,462,249
|
|
G |
Sord |
sorbitol dehydrogenase |
decreases activity |
ISO |
melamine results in decreased activity of SORD protein |
CTD |
PMID:29254411 |
|
NCBI chr 3:109,184,697...109,216,133
Ensembl chr 3:109,184,676...109,216,133
|
|
G |
Spp1 |
secreted phosphoprotein 1 |
multiple interactions |
EXP |
[cyanuric acid co-treated with melamine] results in increased expression of SPP1 mRNA; [melamine co-treated with cyanuric acid] results in increased expression of SPP1 mRNA; [melamine co-treated with cyanuric acid] results in increased expression of SPP1 protein |
CTD |
PMID:21784140 PMID:22610612 PMID:23022069 |
|
NCBI chr14:5,308,885...5,315,120
Ensembl chr14:5,308,885...5,315,162
|
|
G |
Tff3 |
trefoil factor 3 |
decreases expression |
EXP |
melamine results in decreased expression of TFF3 |
CTD |
PMID:23052191 |
|
NCBI chr20:9,193,259...9,197,969
Ensembl chr20:9,193,262...9,198,054
|
|
G |
Tgfb1 |
transforming growth factor, beta 1 |
multiple interactions increases expression |
ISO |
1,2-Dihydroxybenzene-3,5-Disulfonic Acid Disodium Salt inhibits the reaction [melamine results in increased expression of TGFB1 mRNA]; 1,2-Dihydroxybenzene-3,5-Disulfonic Acid Disodium Salt inhibits the reaction [melamine results in increased expression of TGFB1 protein]; manganese(III)-tetrakis(4-benzoic acid)porphyrin inhibits the reaction [melamine results in increased expression of TGFB1 mRNA]; manganese(III)-tetrakis(4-benzoic acid)porphyrin inhibits the reaction [melamine results in increased expression of TGFB1 protein]; SN50 peptide inhibits the reaction [melamine results in increased expression of TGFB1 mRNA]; SN50 peptide inhibits the reaction [melamine results in increased expression of TGFB1 protein]; TGFB1 protein affects the reaction [melamine results in increased cleavage of CASP3 protein]; TGFB1 protein affects the reaction [melamine results in increased cleavage of CASP9 protein]; TGFB1 protein affects the reaction [melamine results in increased expression of BAD protein]; TGFB1 protein affects the reaction [melamine results in increased expression of BAX protein]; TGFB1 protein affects the reaction [melamine results in increased expression of FN1 mRNA]; TGFB1 protein affects the reaction [melamine results in increased expression of FN1 protein] melamine results in increased expression of TGFB1 mRNA; melamine results in increased expression of TGFB1 protein |
CTD |
PMID:22915474 |
|
NCBI chr 1:81,196,532...81,212,848
Ensembl chr 1:81,196,532...81,212,847
|
|
G |
Timp1 |
TIMP metallopeptidase inhibitor 1 |
multiple interactions |
EXP |
[cyanuric acid co-treated with melamine] results in increased expression of TIMP1 mRNA; [melamine co-treated with cyanuric acid] results in increased expression of TIMP1 mRNA |
CTD |
PMID:21784140 PMID:23022069 |
|
NCBI chr X:1,212,969...1,217,714
Ensembl chr X:1,212,972...1,217,664
|
|
G |
Tnfrsf12a |
TNF receptor superfamily member 12A |
increases expression |
EXP |
melamine results in increased expression of TNFRSF12A |
CTD |
PMID:23052191 |
|
NCBI chr10:12,707,077...12,709,071
Ensembl chr10:12,689,890...12,709,045
|
|
G |
Vcam1 |
vascular cell adhesion molecule 1 |
multiple interactions increases expression |
ISO |
1,2-Dihydroxybenzene-3,5-Disulfonic Acid Disodium Salt inhibits the reaction [melamine results in increased expression of VCAM1 mRNA]; 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [melamine results in increased expression of VCAM1 mRNA]; manganese(III)-tetrakis(4-benzoic acid)porphyrin inhibits the reaction [melamine results in increased expression of VCAM1 mRNA]; SB 203580 inhibits the reaction [melamine results in increased expression of VCAM1 mRNA]; SN50 peptide inhibits the reaction [melamine results in increased expression of VCAM1 mRNA] |
CTD |
PMID:22915474 |
|
NCBI chr 2:204,038,120...204,057,852
Ensembl chr 2:204,038,114...204,057,958
|
|
|
G |
Abcc2 |
ATP binding cassette subfamily C member 2 |
multiple interactions |
ISO |
[Dietary Fats co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Captan co-treated with Chlorpyrifos co-treated with thiacloprid co-treated with Thiophanate co-treated with Ziram] results in increased expression of ABCC2 mRNA |
CTD |
PMID:32745781 |
|
NCBI chr 1:242,664,657...242,723,239
Ensembl chr 1:242,664,657...242,723,238
|
|
G |
Abcc3 |
ATP binding cassette subfamily C member 3 |
multiple interactions increases expression |
ISO EXP |
[Dietary Fats co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Captan co-treated with Chlorpyrifos co-treated with thiacloprid co-treated with Thiophanate co-treated with Ziram] results in increased expression of ABCC3 mRNA thiacloprid results in increased expression of ABCC3 mRNA [thiacloprid co-treated with clothianidin] results in increased expression of ABCC3 mRNA; [thiacloprid co-treated with enilconazole] results in increased expression of ABCC3 mRNA |
CTD |
PMID:32745781 PMID:33426623 |
|
NCBI chr10:79,296,681...79,342,749
Ensembl chr10:79,296,693...79,342,595
|
|
G |
Ache |
acetylcholinesterase |
decreases activity |
EXP ISO |
thiacloprid results in decreased activity of ACHE protein |
CTD |
PMID:21251949 |
|
NCBI chr12:19,406,133...19,413,713
Ensembl chr12:19,407,360...19,413,651
|
|
G |
Acox1 |
acyl-CoA oxidase 1 |
multiple interactions |
ISO |
[Ziram co-treated with Thiophanate co-treated with Captan co-treated with Chlorpyrifos co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with thiacloprid] results in increased expression of ACOX1 mRNA |
CTD |
PMID:32736067 |
|
NCBI chr10:101,406,197...101,431,252
Ensembl chr10:101,406,197...101,431,232
|
|
G |
Alb |
albumin |
multiple interactions decreases expression |
EXP |
astaxanthine inhibits the reaction [thiacloprid results in decreased expression of ALB protein] |
CTD |
PMID:34564187 |
|
NCBI chr14:17,607,397...17,622,814
Ensembl chr14:17,607,381...17,622,836
|
|
G |
Aldh1a1 |
aldehyde dehydrogenase 1 family, member A1 |
increases expression multiple interactions |
ISO EXP |
thiacloprid results in increased expression of ALDH1A1 mRNA [thiacloprid co-treated with clothianidin] results in increased expression of ALDH1A1 mRNA; [thiacloprid co-treated with enilconazole] results in increased expression of ALDH1A1 mRNA [thiacloprid co-treated with enilconazole] results in decreased expression of ALDH1A1 mRNA |
CTD |
PMID:32201337 PMID:33426623 |
|
NCBI chr 1:218,000,470...218,152,962
Ensembl chr 1:218,042,127...218,152,961
|
|
G |
Atg5 |
autophagy related 5 |
decreases expression |
ISO |
thiacloprid results in decreased expression of ATG5 mRNA; thiacloprid results in decreased expression of ATG5 protein |
CTD |
PMID:37468076 |
|
NCBI chr20:47,798,217...47,889,216
Ensembl chr20:47,798,290...47,889,209
|
|
G |
Cat |
catalase |
decreases activity multiple interactions decreases expression |
EXP |
thiacloprid results in decreased activity of CAT protein astaxanthine inhibits the reaction [thiacloprid results in decreased activity of CAT protein]; Polysaccharides inhibits the reaction [thiacloprid results in decreased activity of CAT protein]; Polysaccharides inhibits the reaction [thiacloprid results in decreased expression of CAT mRNA] |
CTD |
PMID:28692354 PMID:34564187 |
|
NCBI chr 3:89,842,393...89,874,577
Ensembl chr 3:89,842,399...89,874,478
|
|
G |
Cd36 |
CD36 molecule |
multiple interactions |
ISO |
[Ziram co-treated with Thiophanate co-treated with Captan co-treated with Chlorpyrifos co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with thiacloprid] results in increased expression of CD36 mRNA |
CTD |
PMID:32736067 |
|
NCBI chr 4:17,317,343...17,410,084
Ensembl chr 4:17,354,466...17,513,903
|
|
G |
Ces2h |
carboxylesterase 2H |
multiple interactions |
ISO |
[clothianidin co-treated with thiacloprid] results in increased expression of CES2 protein; [enilconazole co-treated with thiacloprid] results in increased expression of CES2 protein |
CTD |
PMID:32201337 |
|
NCBI chr19:32,974,242...32,988,842
Ensembl chr19:32,974,242...32,988,830
|
|
G |
Chrnb2 |
cholinergic receptor nicotinic beta 2 subunit |
multiple interactions |
EXP |
thiacloprid results in increased activity of [NACHRA8 protein co-treated with CHRNB2 protein]; thiacloprid results in increased activity of [NACHRALPHA1 protein co-treated with CHRNB2 protein] |
CTD |
PMID:16981889 PMID:25459289 |
|
NCBI chr 2:175,181,402...175,189,619
Ensembl chr 2:175,181,402...175,189,619
|
|
G |
Cpt1a |
carnitine palmitoyltransferase 1A |
multiple interactions |
ISO |
[Ziram co-treated with Thiophanate co-treated with Captan co-treated with Chlorpyrifos co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with thiacloprid] results in increased expression of CPT1A mRNA |
CTD |
PMID:32736067 |
|
NCBI chr 1:200,564,634...200,627,059
Ensembl chr 1:200,565,613...200,627,055
|
|
G |
Crem |
cAMP responsive element modulator |
decreases expression |
ISO |
thiacloprid results in decreased expression of CREM mRNA; thiacloprid results in decreased expression of CREM protein |
CTD |
PMID:37468076 |
|
NCBI chr17:54,238,889...54,305,989
Ensembl chr17:54,239,030...54,305,989
|
|
G |
Cybb |
cytochrome b-245 beta chain |
increases expression |
ISO |
thiacloprid results in increased expression of CYBB mRNA |
CTD |
PMID:32201337 |
|
NCBI chr X:13,358,101...13,392,570
Ensembl chr X:13,359,430...13,392,586
|
|
G |
Cyp11a1 |
cytochrome P450, family 11, subfamily a, polypeptide 1 |
decreases expression |
ISO |
thiacloprid results in decreased expression of CYP11A1 mRNA |
CTD |
PMID:37468076 |
|
NCBI chr 8:58,422,807...58,434,342
Ensembl chr 8:58,404,669...58,434,338
|
|
G |
Cyp19a1 |
cytochrome P450, family 19, subfamily a, polypeptide 1 |
increases activity affects expression multiple interactions increases expression |
ISO |
thiacloprid results in increased activity of CYP19A1 protein thiacloprid affects the expression of CYP19A1 mRNA 1-(6-((3-methoxyestra-1,3,5(10)-trien-17-yl)amino)hexyl)-1H-pyrrole-2,5-dione affects the reaction [thiacloprid affects the expression of CYP19A1 mRNA]; 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one affects the reaction [thiacloprid affects the expression of CYP19A1 mRNA] thiacloprid results in increased expression of CYP19A1 mRNA |
CTD |
PMID:26464060 PMID:28750898 PMID:29701941 |
|
NCBI chr 8:54,552,978...54,580,375
Ensembl chr 8:54,553,165...54,580,758
|
|
G |
Cyp1a1 |
cytochrome P450, family 1, subfamily a, polypeptide 1 |
increases expression |
ISO |
thiacloprid results in increased expression of CYP1A1 mRNA; thiacloprid results in increased expression of CYP1A1 protein |
CTD |
PMID:21784029 |
|
NCBI chr 8:58,096,021...58,102,130
Ensembl chr 8:58,096,077...58,102,125
|
|
G |
Cyp1a2 |
cytochrome P450, family 1, subfamily a, polypeptide 2 |
increases expression multiple interactions |
ISO |
thiacloprid results in increased expression of CYP1A2 mRNA; thiacloprid results in increased expression of CYP1A2 protein [enilconazole co-treated with thiacloprid co-treated with clothianidin] results in increased expression of CYP1A2 mRNA; [thiacloprid co-treated with enilconazole] results in increased expression of CYP1A2 mRNA |
CTD |
PMID:21784029 PMID:32201337 |
|
NCBI chr 8:58,075,367...58,082,255
Ensembl chr 8:58,075,367...58,082,312
|
|
G |
Cyp2b2 |
cytochrome P450, family 2, subfamily b, polypeptide 2 |
increases expression multiple interactions |
EXP |
thiacloprid results in increased expression of CYP2B2 mRNA [thiacloprid co-treated with clothianidin] results in increased expression of CYP2B2 mRNA; [thiacloprid co-treated with enilconazole] results in increased expression of CYP2B2 mRNA |
CTD |
PMID:33426623 |
|
NCBI chr 1:81,594,534...81,608,567
Ensembl chr 1:81,594,555...81,608,566
|
|
G |
Cyp2b3 |
cytochrome P450, family 2, subfamily b, polypeptide 3 |
multiple interactions increases expression |
ISO |
[clothianidin co-treated with thiacloprid] results in increased expression of CYP2B6 protein; [enilconazole co-treated with thiacloprid] results in increased expression of CYP2B6 protein; [enilconazole co-treated with thiacloprid] results in increased expression of CYP2B9 protein; [thiacloprid co-treated with enilconazole] results in increased expression of CYP2B6 mRNA [Dietary Fats co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Captan co-treated with Chlorpyrifos co-treated with thiacloprid co-treated with Thiophanate co-treated with Ziram] results in increased expression of CYP2B10 mRNA; [Ziram co-treated with Thiophanate co-treated with Captan co-treated with Chlorpyrifos co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with thiacloprid] results in increased expression of CYP2B10 mRNA thiacloprid results in increased expression of CYP2B6 mRNA |
CTD |
PMID:32201337 PMID:32736067 PMID:32745781 |
|
NCBI chr 1:81,652,762...81,732,153
Ensembl chr 1:81,652,787...81,732,143
|
|
G |
Cyp2c24 |
cytochrome P450, family 2, subfamily c, polypeptide 24 |
multiple interactions |
ISO |
[Ziram co-treated with Thiophanate co-treated with Captan co-treated with Chlorpyrifos co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with thiacloprid] results in increased expression of CYP2C55 mRNA |
CTD |
PMID:32736067 |
|
NCBI chr 1:236,873,967...236,936,238
Ensembl chr 1:236,873,967...236,936,238
|
|
G |
Cyp2c6 |
cytochrome P450, family 2, subfamily C, polypeptide 6 |
increases expression multiple interactions decreases expression |
ISO |
thiacloprid results in increased expression of CYP2C19 mRNA [Dietary Fats co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Captan co-treated with Chlorpyrifos co-treated with thiacloprid co-treated with Thiophanate co-treated with Ziram] results in increased expression of CYP2C29 mRNA thiacloprid results in decreased expression of CYP2C19 protein |
CTD |
PMID:32194361 PMID:32201337 PMID:32745781 |
|
NCBI chr 1:237,938,521...237,976,238
Ensembl chr 1:237,693,094...238,057,596
|
|
G |
Cyp2e1 |
cytochrome P450, family 2, subfamily e, polypeptide 1 |
decreases expression multiple interactions |
ISO |
thiacloprid results in decreased expression of CYP2E1 mRNA [clothianidin co-treated with thiacloprid] results in increased expression of CYP2E1 protein; [enilconazole co-treated with thiacloprid co-treated with clothianidin] results in decreased expression of CYP2E1 mRNA; [thiacloprid co-treated with clothianidin] results in decreased expression of CYP2E1 mRNA; [thiacloprid co-treated with enilconazole] results in decreased expression of CYP2E1 mRNA |
CTD |
PMID:32201337 |
|
NCBI chr 1:195,840,330...195,850,728
Ensembl chr 1:195,840,058...195,864,023
|
|
G |
Cyp3a2 |
cytochrome P450, family 3, subfamily a, polypeptide 2 |
increases expression multiple interactions |
ISO |
thiacloprid results in increased expression of CYP3A4 mRNA; thiacloprid results in increased expression of CYP3A4 protein [clothianidin co-treated with thiacloprid] results in increased expression of CYP3A4 protein; [enilconazole co-treated with thiacloprid co-treated with clothianidin] results in increased expression of CYP3A4 mRNA; [enilconazole co-treated with thiacloprid] results in increased expression of CYP3A4 protein; [thiacloprid co-treated with enilconazole] results in increased expression of CYP3A4 mRNA |
CTD |
PMID:32201337 |
|
NCBI chr12:9,207,978...9,230,064
Ensembl chr12:9,015,383...9,285,008
|
|
G |
Cyp3a23-3a1 |
cytochrome P450, family 3, subfamily a, polypeptide 23-polypeptide 1 |
multiple interactions increases expression |
EXP |
[thiacloprid co-treated with clothianidin] results in increased expression of CYP3A23-3A1 mRNA; [thiacloprid co-treated with enilconazole] results in increased expression of CYP3A23-3A1 mRNA thiacloprid results in increased expression of CYP3A23-3A1 mRNA |
CTD |
PMID:33426623 |
|
NCBI chr12:9,256,159...9,285,020
Ensembl chr12:9,254,475...9,285,030 Ensembl chr12:9,254,475...9,285,030
|
|
G |
Cyp3a9 |
cytochrome P450, family 3, subfamily a, polypeptide 9 |
increases expression multiple interactions |
ISO |
thiacloprid results in increased expression of CYP3A5 mRNA [enilconazole co-treated with thiacloprid] results in increased expression of CYP3A5 protein; [thiacloprid co-treated with clothianidin] results in increased expression of CYP3A5 mRNA |
CTD |
PMID:32201337 |
|
NCBI chr12:16,806,222...16,846,428
Ensembl chr12:16,806,207...16,846,422
|
|
G |
Cyp7a1 |
cytochrome P450 family 7 subfamily A member 1 |
decreases expression multiple interactions |
ISO EXP |
thiacloprid results in decreased expression of CYP7A1 protein thiacloprid results in decreased expression of CYP7A1 mRNA [thiacloprid co-treated with clothianidin] results in decreased expression of CYP7A1 mRNA; [thiacloprid co-treated with enilconazole] results in decreased expression of CYP7A1 mRNA |
CTD |
PMID:32194361 PMID:33426623 |
|
NCBI chr 5:19,376,979...19,386,676
Ensembl chr 5:19,376,974...19,386,688
|
|
G |
Ddx4 |
DEAD-box helicase 4 |
decreases expression |
ISO |
thiacloprid results in decreased expression of DDX4 mRNA; thiacloprid results in decreased expression of DDX4 protein |
CTD |
PMID:37468076 |
|
NCBI chr 2:44,227,946...44,282,867
Ensembl chr 2:44,227,946...44,282,723
|
|
G |
Dio1 |
iodothyronine deiodinase 1 |
multiple interactions |
ISO |
[Dietary Fats co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Captan co-treated with Chlorpyrifos co-treated with thiacloprid co-treated with Thiophanate co-treated with Ziram] results in increased expression of DIO1 mRNA |
CTD |
PMID:32745781 |
|
NCBI chr 5:122,074,285...122,090,983
Ensembl chr 5:122,074,279...122,090,970
|
|
G |
Eci1 |
enoyl-CoA delta isomerase 1 |
multiple interactions |
ISO |
[Ziram co-treated with Thiophanate co-treated with Captan co-treated with Chlorpyrifos co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with thiacloprid] results in increased expression of ECI1 mRNA |
CTD |
PMID:32736067 |
|
NCBI chr10:13,456,715...13,470,061
Ensembl chr10:13,456,563...13,470,061
|
|
G |
Eln |
elastin |
multiple interactions decreases expression |
EXP |
[thiacloprid co-treated with clothianidin] results in decreased expression of ELN mRNA; [thiacloprid co-treated with enilconazole] results in decreased expression of ELN mRNA thiacloprid results in decreased expression of ELN mRNA |
CTD |
PMID:33426623 |
|
NCBI chr12:21,968,544...22,011,929
Ensembl chr12:21,968,544...22,011,928
|
|
G |
Gfap |
glial fibrillary acidic protein |
multiple interactions |
ISO |
[Ziram co-treated with Thiophanate co-treated with Captan co-treated with Chlorpyrifos co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with thiacloprid] results in increased expression of GFAP protein |
CTD |
PMID:32736067 |
|
NCBI chr10:87,852,891...87,861,631
Ensembl chr10:87,852,890...87,861,589
|
|
G |
Gpt |
glutamic--pyruvic transaminase |
increases expression multiple interactions |
EXP |
thiacloprid results in increased expression of GPT protein astaxanthine inhibits the reaction [thiacloprid results in increased expression of GPT protein]; Polysaccharides inhibits the reaction [thiacloprid results in increased expression of GPT protein] |
CTD |
PMID:31328355 PMID:34564187 |
|
NCBI chr 7:108,416,646...108,419,495
Ensembl chr 7:108,416,642...108,419,494
|
|
G |
Gpx1 |
glutathione peroxidase 1 |
multiple interactions decreases expression |
EXP |
Polysaccharides inhibits the reaction [thiacloprid results in decreased expression of GPX1 mRNA] |
CTD |
PMID:28692354 |
|
NCBI chr 8:109,026,905...109,028,031
Ensembl chr 8:109,026,905...109,028,024
|
|
G |
Hmgb1 |
high mobility group box 1 |
multiple interactions increases expression |
EXP |
astaxanthine inhibits the reaction [thiacloprid results in increased expression of HMGB1 mRNA] |
CTD |
PMID:34564187 |
|
NCBI chr12:5,972,950...5,979,658
Ensembl chr12:5,901,586...5,978,565 Ensembl chr16:5,901,586...5,978,565
|
|
G |
Hmgcs2 |
3-hydroxy-3-methylglutaryl-CoA synthase 2 |
multiple interactions |
ISO |
[Dietary Fats co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Captan co-treated with Chlorpyrifos co-treated with thiacloprid co-treated with Thiophanate co-treated with Ziram] results in increased expression of HMGCS2 mRNA |
CTD |
PMID:32745781 |
|
NCBI chr 2:185,875,609...185,903,505
Ensembl chr 2:185,875,616...185,902,130
|
|
G |
Il10 |
interleukin 10 |
increases expression multiple interactions |
EXP |
thiacloprid results in increased expression of IL10 protein astaxanthine inhibits the reaction [thiacloprid results in increased expression of IL10 protein] |
CTD |
PMID:34564187 |
|
NCBI chr13:42,472,625...42,477,308
Ensembl chr13:42,472,839...42,477,313
|
|
G |
Il1b |
interleukin 1 beta |
increases expression multiple interactions |
EXP |
thiacloprid results in increased expression of IL1B protein astaxanthine inhibits the reaction [thiacloprid results in increased expression of IL1B protein] |
CTD |
PMID:34564187 |
|
NCBI chr 3:116,577,005...116,583,386
Ensembl chr 3:116,577,010...116,583,415
|
|
G |
Il6 |
interleukin 6 |
increases expression |
EXP |
thiacloprid results in increased expression of IL6 protein |
CTD |
PMID:34564187 |
|
NCBI chr 4:5,214,602...5,219,178
Ensembl chr 4:5,213,394...5,219,178
|
|
G |
Ins1 |
insulin 1 |
multiple interactions |
ISO |
[Dietary Fats co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Captan co-treated with Chlorpyrifos co-treated with thiacloprid co-treated with Thiophanate co-treated with Ziram] results in increased expression of INS1 protein |
CTD |
PMID:32745781 |
|
NCBI chr 1:251,244,973...251,245,540
Ensembl chr 1:251,244,973...251,245,536
|
|
G |
Ky |
kyphoscoliosis peptidase |
decreases expression multiple interactions |
EXP |
thiacloprid results in decreased expression of KY mRNA [thiacloprid co-treated with clothianidin] results in decreased expression of KY mRNA; [thiacloprid co-treated with enilconazole] results in decreased expression of KY mRNA |
CTD |
PMID:33426623 |
|
NCBI chr 8:103,086,959...103,126,305
Ensembl chr 8:103,086,630...103,126,024
|
|
G |
Megf11 |
multiple EGF-like-domains 11 |
decreases expression multiple interactions |
EXP |
thiacloprid results in decreased expression of MEGF11 mRNA [thiacloprid co-treated with clothianidin] results in decreased expression of MEGF11 mRNA; [thiacloprid co-treated with enilconazole] results in decreased expression of MEGF11 mRNA |
CTD |
PMID:33426623 |
|
NCBI chr 8:64,892,312...65,218,984
Ensembl chr 8:64,892,387...65,216,061
|
|
G |
Mki67 |
marker of proliferation Ki-67 |
decreases expression |
ISO |
thiacloprid results in decreased expression of MKI67 mRNA; thiacloprid results in decreased expression of MKI67 protein |
CTD |
PMID:37468076 |
|
NCBI chr 1:190,496,319...190,522,983
Ensembl chr 1:190,496,319...190,522,762
|
|
G |
Mme |
membrane metallo-endopeptidase |
increases expression multiple interactions |
EXP |
thiacloprid results in increased expression of MME mRNA [thiacloprid co-treated with clothianidin] results in increased expression of MME mRNA; [thiacloprid co-treated with enilconazole] results in increased expression of MME mRNA |
CTD |
PMID:33426623 |
|
NCBI chr 2:147,686,913...147,803,808
Ensembl chr 2:147,722,086...147,803,792
|
|
G |
Nos2 |
nitric oxide synthase 2 |
increases expression multiple interactions |
EXP |
thiacloprid results in increased expression of NOS2 mRNA astaxanthine inhibits the reaction [thiacloprid results in increased expression of NOS2 mRNA] |
CTD |
PMID:34564187 |
|
NCBI chr10:63,815,308...63,851,208
Ensembl chr10:63,815,308...63,851,210
|
|
G |
Nr1i3 |
nuclear receptor subfamily 1, group I, member 3 |
multiple interactions |
ISO |
NR1I3 protein affects the susceptibility to [2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Captan co-treated with Chlorpyrifos co-treated with Thiophanate co-treated with thiacloprid co-treated with Ziram] |
CTD |
PMID:29950287 |
|
NCBI chr13:83,632,940...83,638,193
Ensembl chr13:83,632,899...83,637,906
|
|
G |
Pdgfrb |
platelet derived growth factor receptor beta |
multiple interactions |
ISO |
[Ziram co-treated with Thiophanate co-treated with Captan co-treated with Chlorpyrifos co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with thiacloprid] results in increased expression of PDGFRB protein |
CTD |
PMID:32736067 |
|
NCBI chr18:54,499,962...54,538,840
Ensembl chr18:54,499,964...54,538,843
|
|
G |
Por |
cytochrome p450 oxidoreductase |
increases expression |
ISO |
thiacloprid results in increased expression of POR mRNA |
CTD |
PMID:32201337 |
|
NCBI chr12:20,951,058...20,999,198
Ensembl chr12:20,951,058...20,999,245
|
|
G |
Serpine1 |
serpin family E member 1 |
multiple interactions |
ISO |
[Dietary Fats co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Captan co-treated with Chlorpyrifos co-treated with thiacloprid co-treated with Thiophanate co-treated with Ziram] results in increased expression of SERPINE1 mRNA |
CTD |
PMID:32745781 |
|
NCBI chr12:19,601,272...19,611,657
Ensembl chr12:19,601,272...19,611,657
|
|
G |
Slc16a2 |
solute carrier family 16 member 2 |
multiple interactions |
ISO |
[Dietary Fats co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Captan co-treated with Chlorpyrifos co-treated with thiacloprid co-treated with Thiophanate co-treated with Ziram] results in increased expression of SLC16A2 mRNA |
CTD |
PMID:32745781 |
|
NCBI chr X:68,725,365...68,848,572
Ensembl chr X:68,723,261...68,848,771
|
|
G |
Slc22a1 |
solute carrier family 22 member 1 |
increases activity |
ISO |
thiacloprid metabolite results in increased activity of SLC22A1 protein; thiacloprid results in increased activity of SLC22A1 protein |
CTD |
PMID:31364238 |
|
NCBI chr 1:48,076,657...48,103,679
Ensembl chr 1:48,076,666...48,103,678
|
|
G |
Slc22a2 |
solute carrier family 22 member 2 |
decreases activity |
ISO |
thiacloprid metabolite results in decreased activity of SLC22A2 protein; thiacloprid results in decreased activity of SLC22A2 protein |
CTD |
PMID:31364238 |
|
NCBI chr 1:48,121,061...48,163,268
Ensembl chr 1:48,121,061...48,163,268
|
|
G |
Slc22a8 |
solute carrier family 22 member 8 |
decreases activity |
ISO |
thiacloprid metabolite results in decreased activity of SLC22A8 protein; thiacloprid results in decreased activity of SLC22A8 protein |
CTD |
PMID:31364238 |
|
NCBI chr 1:205,496,331...205,516,378
Ensembl chr 1:205,498,084...205,517,450
|
|
G |
Slc6a1 |
solute carrier family 6 member 1 |
decreases expression multiple interactions |
EXP |
thiacloprid results in decreased expression of SLC6A1 mRNA [thiacloprid co-treated with clothianidin] results in decreased expression of SLC6A1 mRNA; [thiacloprid co-treated with enilconazole] results in decreased expression of SLC6A1 mRNA |
CTD |
PMID:33426623 |
|
NCBI chr 4:147,448,961...147,482,295
Ensembl chr 4:147,466,965...147,482,293
|
|
G |
Sod1 |
superoxide dismutase 1 |
multiple interactions decreases expression |
EXP |
Polysaccharides inhibits the reaction [thiacloprid results in decreased expression of SOD1 mRNA] |
CTD |
PMID:28692354 |
|
NCBI chr11:29,456,673...29,462,249
Ensembl chr11:29,456,558...29,462,249
|
|
G |
Star |
steroidogenic acute regulatory protein |
decreases expression |
ISO |
thiacloprid results in decreased expression of STAR mRNA |
CTD |
PMID:37468076 |
|
NCBI chr16:66,267,094...66,274,368
Ensembl chr16:66,264,807...66,271,672
|
|
G |
Sult1b1 |
sulfotransferase family 1B member 1 |
multiple interactions |
ISO |
[Dietary Fats co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Captan co-treated with Chlorpyrifos co-treated with thiacloprid co-treated with Thiophanate co-treated with Ziram] results in increased expression of SULT1B1 mRNA |
CTD |
PMID:32745781 |
|
NCBI chr14:20,492,763...20,505,491
Ensembl chr14:20,492,708...20,505,483
|
|
G |
Sycp3 |
synaptonemal complex protein 3 |
decreases expression |
ISO |
thiacloprid results in decreased expression of SYCP3 mRNA; thiacloprid results in decreased expression of SYCP3 protein |
CTD |
PMID:37468076 |
|
NCBI chr 7:22,874,055...22,888,512
Ensembl chr 7:22,874,055...22,888,511
|
|
G |
Thrsp |
thyroid hormone responsive |
multiple interactions |
ISO |
[2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Captan co-treated with Chlorpyrifos co-treated with thiacloprid co-treated with Thiophanate co-treated with Ziram] results in increased expression of THRSP mRNA; [Dietary Fats co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Captan co-treated with Chlorpyrifos co-treated with thiacloprid co-treated with Thiophanate co-treated with Ziram] results in decreased expression of THRSP mRNA; Dietary Fats inhibits the reaction [[2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Captan co-treated with Chlorpyrifos co-treated with thiacloprid co-treated with Thiophanate co-treated with Ziram] results in increased expression of THRSP mRNA] |
CTD |
PMID:32745781 |
|
NCBI chr 1:151,723,415...151,727,740
Ensembl chr 1:151,723,086...151,728,075
|
|